Physiologically based pharmacokinetic model for voriconazole in presence of liver impairment
AIM:To predict voriconazole(VCZ)'s pharmacokinetics in patients with different degree of liver dysfunction.METHODS:The physiological based pharmacokinetics(PBPK)models were devel-oped for VCZ based on drug's physico-chemical property and in-vitro data.Then liver dysfunction induced changes in physiological,anatomical pa-rameter was integrated into the PBPK model.The clinical verified VCZ model was used to predict VCZ's PK in patients of different CYP2C19 genotype with different degree of liver dysfunction.RESULTS:The PBPK predicted the VCZ exposure in the pa-tients with liver dysfunction with acceptable predic-tion error.CONCLUSION:The PBPK model devel-oped here could evaluate the impact of liver dys-function and CYP2C19 genotype on VCZ's pharma-cokinetics and support individual dose adjustment of VCZ.
万方数据
维普
